FBRXForte Biosciences Inc
$17.15
$0.18
(1.06%)
Closed $16.82
$0.33
(1.96%)
After Hours
Mkt Cap$348.14M
Vol254,561.00
Fundamentals
Mkt Cap
$348.14M
Volume
-
52W High
$35.80
52W Low
$9.10
PE Ratio
-3.29
Avg. Volume
219,384.20
EPS (Annual)
-$4.71
Rev/Employee
$0.00
Earnings
-
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing...
Business Wire
Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its first quarter 2026...
Business Wire
Wall Street Zen Upgrades Forte Biosciences (NASDAQ:FBRX) to "Sell"
Wall Street Zen upgraded shares of Forte Biosciences from a 'strong sell' rating to a 'sell' rating in a research note on Saturday...
MarketBeat
Stock Traders Purchase High Volume of Call Options on Forte Biosciences (NASDAQ:FBRX)
Forte Biosciences, Inc. (NASDAQ:FBRX - Get Free Report) saw some unusual options trading on Wednesday. Investors acquired 30,205 call options on the stock. This represents an increase of 1,663% compared to the average volume of 1,713 call options...
MarketBeat
Forte Biosciences, Inc. (NASDAQ:FBRX) Short Interest Update
Forte Biosciences, Inc. (NASDAQ:FBRX - Get Free Report) was the recipient of a significant growth in short interest in the month of March. As of March 31st, there was short interest totaling 892,176...
MarketBeat
Forte Biosciences Sees Unusually Large Options Volume (NASDAQ:FBRX)
Forte Biosciences, Inc. (NASDAQ:FBRX - Get Free Report) was the target of unusually large options trading activity on Wednesday. Investors purchased 30,205 call options on the company. This...
MarketBeat
Brookline Capital Markets Predicts FBRX FY2026 Earnings
Forte Biosciences, Inc. (NASDAQ:FBRX - Free Report) - Analysts at Brookline Capital Markets decreased their FY2026 earnings estimates for Forte Biosciences in a research note issued on Monday, April 6th. Brookline Capital Markets analyst K. Raja now anticipates that the company will post earnings pe...
MarketBeat
Forte Biosciences Announces Pricing of $150 Million Public Offering
Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,709,936...
Business Wire
Forte Biosciences Announces Proposed Public Offering
Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced that it has commenced an underwritten public...
Business Wire
Analysts Issue Forecasts for FBRX FY2030 Earnings
Forte Biosciences, Inc. (NASDAQ:FBRX - Free Report) - Investment analysts at Brookline Capital Markets issued their FY2030 EPS estimates for shares of Forte Biosciences in a research note issued to investors on Monday, April 6th. Brookline Capital Markets analyst K. Raja expects that the company wil...
MarketBeat
<
1
2
...
>